Skip to main content
SpringerLink
Log in

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

18F-fluorodeoxyglucose (FDG) PET is a non-invasive imaging technique recommended for the management of both diffuse large B-cell and Hodgkin’s lymphomas. This retrospective study investigated the value of FDG PET for initial staging and its prognostic impact on patients with mantle cell lymphoma (MCL).

Methods

A total of 44 untreated MCL patients assessed by both conventional evaluations (CE) and FDG PET for initial staging were included. The maximum standardized uptake value (SUVmax) in the most intense pathological area was recorded for each patient. Disease status after chemotherapy completion was assessed according to the International Workshop Criteria (IWC) for non-Hodgkin’s lymphoma (NHL) response and IWC+PET.

Results

FDG PET uptakes at diagnosis were abnormal in all cases. Compared to CT scan, nodal and extranodal sites were only detected by FDG PET. Due to insufficient sensibility for bone marrow (BM) and gastrointestinal (GI) involvement, FDG PET did not modify initial staging. Positive and negative predictive values of IWC+PET for relapse at 1 year were 62.5 and 100%. With a median follow-up of 21 months, only the International Prognostic Index (IPI) and IWC+PET modified both event-free survival (EFS) (p = .02 and .0001, respectively) and overall survival (p = .03 and .05, respectively) duration. When combining IPI and SUVmax at diagnosis, we were able to identify patients with low (29%; no relapse/progression), intermediate (42%; median EFS: 37 months) and high risk (29%, median EFS: 22 months) (p = .004).

Conclusion

In MCL, FDG PET at diagnosis is complementary to CE, but BM and GI biopsies remain mandatory. IWC+PET criteria are highly efficient to identify patients with high risk for early relapse. Combining IPI and SUVmax may predict patient outcome and warrant further prospective investigations towards designing risk-adapted strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791–8.

    Article  PubMed  Google Scholar 

  2. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–8.

    Article  PubMed  Google Scholar 

  3. Bernard M, Gressin R, Lefrère F, Drénou B, Branger B, Caulet-Maugendre S, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001;15:1785–91.

    Article  CAS  PubMed  Google Scholar 

  4. Determann O, Hoster E, Ott G, Wolfram BH, Loddenkemper C, Hansmann ML, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–7.

    Article  CAS  PubMed  Google Scholar 

  5. Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.

    Article  PubMed  Google Scholar 

  6. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–65.

    Article  CAS  PubMed  Google Scholar 

  7. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008;112:2583; author reply 2583–4.

    Article  CAS  PubMed  Google Scholar 

  8. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27:4365–70.

    Article  CAS  PubMed  Google Scholar 

  9. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006;12:1270–6.

    Article  CAS  PubMed  Google Scholar 

  10. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006;107:2271–8.

    Article  CAS  PubMed  Google Scholar 

  11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.

    Article  PubMed  Google Scholar 

  12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.

    CAS  PubMed  Google Scholar 

  13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.

  14. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94.

  15. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–8.

    Article  PubMed  Google Scholar 

  16. Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008;49:1693–701.

    Article  PubMed  Google Scholar 

  17. Gill S, Wolf M, Prince HM, Januszewicz H, Ritchie D, Hicks RJ, et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008;8:159–65.

    Article  PubMed  Google Scholar 

  18. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:4643–51.

    Article  PubMed  Google Scholar 

  19. Bodet-Milin C, Kraeber-Bodere F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93:471–2.

    Article  PubMed  Google Scholar 

  20. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267–73.

    PubMed  Google Scholar 

  21. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750–62.

    Article  CAS  PubMed  Google Scholar 

  22. Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, et al. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun 2009;30:770–8.

    Article  PubMed  Google Scholar 

  23. Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009. Epub ahead of print.

  24. Andersen NS, Jensen MK, de Nully Brown P, Geisler CH. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401–8.

    Article  CAS  PubMed  Google Scholar 

  25. Bosch F, López-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567–75.

    Article  CAS  PubMed  Google Scholar 

  26. Moller MB, Pedersen NT, Christensen BE. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. Br J Haematol 2006;133:43–9.

    Article  CAS  PubMed  Google Scholar 

  27. Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Bodet-Milin was supported by a grant from IBA. Dr. S. Le Gouill is supported by grants from the “Institut National du cancer (INCa)” and the “Région Pays de la Loire” (France).

Author information

Authors and Affiliations

  1. Service de médecine nucléaire, CHU de Nantes, Nantes, France

    Caroline Bodet-Milin & Françoise Kraeber-Bodere

  2. Centre de recherche en cancérologie Nantes/Angers, INSERM UMR 892, Nantes, France

    Caroline Bodet-Milin, Cyrille Touzeau, Mohamad Mohty, Françoise Kraeber-Bodere & Steven Le Gouill

  3. Service d’hématologie clinique, CHU de Nantes, Place Alexis Ricordeau, 44093, Nantes cedex 1, France

    Cyrille Touzeau, Mohamad Mohty, Philippe Moreau & Steven Le Gouill

  4. Registre du cancer Loire-Atlantique et Vendée, Nantes, France

    Christophe Leux

  5. Service d’hématologie clinique du CHU de Grenoble, Grenoble, France

    Mehmet Sahin & Rémy Gressin

  6. Service d’anatomopathologie du CHU de Nantes, Nantes, France

    Anne Moreau

  7. Service d’hématologie clinique du CHD de La Roche-sur-Yon, La Roche-sur-Yon, France

    Hervé Maisonneuve

  8. Centre Catherine de Sienne, Nantes, France

    Nadine Morineau & Pascal Gries

  9. Service d’hématologie clinique de Vannes, Vannes, France

    Henry Jardel

  10. Service d’hématologie clinique de Lorient, Lorient, France

    Philippe Moreau

  11. Service de médecine nucléaire du CHU de Grenoble, Grenoble, France

    Céline Gallazini-Crépin

  12. Institut Albert Bonniot, INSERM U823, Joseph Fourier University, Grenoble, France

    Rémy Gressin

  13. Centre régional de lutte contre le Cancer René Gauducheau, Saint-Herblain, France

    Jean-Luc Harousseau & Françoise Kraeber-Bodere

  14. Centre d’Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France

    Mohamad Mohty & Steven Le Gouill

Authors
  1. Caroline Bodet-Milin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyrille Touzeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christophe Leux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hervé Maisonneuve
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nadine Morineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henry Jardel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Philippe Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Céline Gallazini-Crépin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pascal Gries
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rémy Gressin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jean-Luc Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Philippe Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Françoise Kraeber-Bodere
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Steven Le Gouill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Le Gouill.

Additional information

Caroline Bodet-Milin and Cyrille Touzeau contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bodet-Milin, C., Touzeau, C., Leux, C. et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 37, 1633–1642 (2010). https://doi.org/10.1007/s00259-010-1469-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1469-2

Keywords

Search

Navigation